Cellectis (CLLS) Research & Development (2015 - 2026)
Cellectis (CLLS) posted Research & Development of -$27.2 million for Q1 2026, down 11.26% on a QoQ basis from -$24.4 million in Q4 2025, and down 23.96% year-over-year from -$35.8 million in Q1 2025.
Cellectis (CLLS) has 12 years of Research & Development data on file, last reported at -$27.2 million in Q1 2026.
- In Q1 2026, Research & Development fell 23.96% year-over-year to -$27.2 million; the TTM figure through Mar 2026 stood at -$98.8 million (down 208.63% YoY), while the FY2025 annual figure was -$93.5 million, down 203.29% from the prior year.
- Research & Development slipped to -$27.2 million in Q1 2026, from -$24.4 million in the prior quarter.
- Across five years, Research & Development topped out at $160.2 million in Q4 2024 and bottomed at -$27.2 million in Q1 2026.
- A 5-year average of -$2.4 million and a median of -$23.1 million in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development jumped 801.42% — and 2025, when it slumped 115.25%.
- Year by year, Research & Development stood at -$21.4 million in 2022, then jumped by 801.42% to $150.3 million in 2023, then grew by 6.57% to $160.2 million in 2024, then slumped by 115.25% to -$24.4 million in 2025, then declined by 11.26% to -$27.2 million in 2026.
- The last three Research & Development figures came in at -$27.2 million (Q1 2026), -$24.4 million (Q4 2025), and -$24.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | -27.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.19 Mn |
| Dec 31, 2025 | -24.44 Mn |
| Sep 30, 2025 | -24.07 Mn |
| Jun 30, 2025 | -23.08 Mn |
| Mar 31, 2025 | -21.93 Mn |
| Dec 31, 2024 | 160.21 Mn |
| Sep 30, 2024 | -23.83 Mn |
| Jun 30, 2024 | -23.52 Mn |
| Mar 31, 2024 | -22.32 Mn |
| Dec 31, 2023 | 150.34 Mn |
| Sep 30, 2023 | -19.08 Mn |
| Jun 30, 2023 | -22.20 Mn |
| Mar 31, 2023 | -21.42 Mn |
| Dec 31, 2022 | -21.43 Mn |
| Sep 30, 2022 | -23.84 Mn |
| Jun 30, 2022 | -25.63 Mn |
| Mar 31, 2022 | -26.60 Mn |
| Dec 31, 2021 | -29.54 Mn |
| Sep 30, 2021 | -34.32 Mn |
| Jun 30, 2021 | -31.15 Mn |
| Mar 31, 2021 | -31.00 Mn |
| Dec 31, 2020 | 23.40 Mn |
| Sep 30, 2020 | -20.10 Mn |
| Jun 30, 2020 | -22.86 Mn |
| Mar 31, 2020 | -20.72 Mn |
| Dec 31, 2019 | -30.33 Mn |
| Sep 30, 2019 | -21.60 Mn |
| Jun 30, 2019 | -25.42 Mn |
| Mar 31, 2019 | -14.51 Mn |
| Dec 31, 2018 | -21.27 Mn |
| Sep 30, 2018 | -18.69 Mn |
| Jun 30, 2018 | -18.04 Mn |
| Mar 31, 2018 | -18.40 Mn |
| Dec 31, 2017 | -20.70 Mn |
| Sep 30, 2017 | -20.29 Mn |
| Jun 30, 2017 | -18.61 Mn |
| Mar 31, 2017 | -19.58 Mn |
| Dec 31, 2016 | -20.15 Mn |
| Sep 30, 2016 | -15.43 Mn |
| Jun 30, 2016 | -22.06 Mn |
| Mar 31, 2016 | -20.81 Mn |
| Dec 31, 2015 | -17.58 Mn |
| Sep 30, 2015 | -17.97 Mn |
| Jun 30, 2015 | -14.13 Mn |
| Mar 31, 2015 | -8.40 Mn |